Measuring the success of treatment for chronic obstructive pulmonary disease - patient, physician and healthcare payer perspectives

被引:12
|
作者
Van Der Molen, T
Pieters, W
Bellamy, D
Taylor, R
机构
[1] Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England
[2] Univ Groningen Hosp, Dept Gen Practice, Groningen, Netherlands
[3] Univ Aberdeen, Dept Gen Practice & Primary Care, Aberdeen AB9 1FX, Scotland
[4] Elkerliek Hosp, Dept Pulm Dis, Helmond, Netherlands
[5] James Fisher Med Ctr, Bournemouth, Dorset, England
关键词
chronic obstructive pulmonary disease; health outcome measures; patients; physicians; healtcare payers; exacerbation rate;
D O I
10.1016/S0954-6111(02)80030-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The success of treatments for chronic obstructive pulmonary disease (COPD) is evaluated by measuring the impact on a range of health outcomes. However, outcome measures differ in their relative importance to the various stakeholder groups. Patients are most interested in the impact on quality of life and on mortality, while physicians also value information about the effect of treatments on lung function and disease progression. In contrast to patients and physicians, healthcare payers take a population perspective, and need to balance the health gains achieved and the costs of treatment. If the management of COPD is to be improved, it is important, first, to understand the outcomes of importance to each relevant stakeholder group, and then second, to refocus the measures in terms that all stakeholders can value. (C) 2002 Elsevier Science Ltd.
引用
收藏
页码:S17 / S21
页数:5
相关论文
共 50 条
  • [21] Treatment of chronic obstructive pulmonary disease
    Sauleda, J
    Batle, S
    Agustí, AGN
    REVISTA CLINICA ESPANOLA, 2001, 201 (07): : 417 - 423
  • [22] Treatment of chronic obstructive pulmonary disease
    Kocyigit, Emine
    NOBEL MEDICUS, 2007, 3 (01): : 4 - 11
  • [23] A Patient Charter for Chronic Obstructive Pulmonary Disease
    John R. Hurst
    Tonya Winders
    Heinrich Worth
    Mohit Bhutani
    Kevin Gruffydd-Jones
    Daiana Stolz
    Mark T. Dransfield
    Advances in Therapy, 2021, 38 : 11 - 23
  • [24] Erythrocytosis in a patient with chronic obstructive pulmonary disease
    Vicari, AM
    Ponzoni, M
    Alberetto, M
    Martani, C
    Pontiroli, AE
    Folli, F
    HAEMATOLOGICA, 1998, 83 (02) : 183 - 186
  • [25] Chromoblastomycosis in a patient with chronic obstructive pulmonary disease
    Okan, G
    Rendon, M
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2001, 15 (02) : 188 - 189
  • [26] Bromoderma in a patient with chronic obstructive pulmonary disease
    Peer, Xavier
    Zwain, Ahmed
    Subnikova, Marina
    Taibjee, Saleem
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 24 - 24
  • [27] Physician-Patient Concordance In The Management Of Us Patients With Chronic Obstructive Pulmonary Disease (COPD)
    Turner, S. J.
    Nazareth, T.
    Mastrangelo, A.
    Small, M. P.
    Lees, A. T.
    Johns, N. R.
    Bailey, J. T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [28] Anaesthesia for patient with chronic obstructive pulmonary disease
    Duggappa, Devika Rani
    Rao, G. Venkateswara
    Kannan, Sudheesh
    INDIAN JOURNAL OF ANAESTHESIA, 2015, 59 (09) : 574 - 583
  • [29] Chronic obstructive pulmonary disease in the older patient
    Nazir, Shoab A.
    Al-Hamed, Mohammad M.
    Erbland, Marcia L.
    CLINICS IN CHEST MEDICINE, 2007, 28 (04) : 703 - 715
  • [30] A Patient Charter for Chronic Obstructive Pulmonary Disease
    Hurst, John R.
    Winders, Tonya
    Worth, Heinrich
    Bhutani, Mohit
    Gruffydd-Jones, Kevin
    Stolz, Daiana
    Dransfield, Mark T.
    ADVANCES IN THERAPY, 2021, 38 (01) : 11 - 23